Trial · NCT07887646
A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies
NCT07887646, Phase 1, Not yet recruiting, BeOne Medicines
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies. Trials, record NCT07887646. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07887646
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies
- NCT number
- NCT07887646
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 70 participants, estimated
- Lead sponsor
- BeOne Medicines
- Conditions
- Diffuse Large B-Cell Lymphoma, B-cell Malignancies
- Interventions
- BG-T0920
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part 1a : Number of Participants Experiencing Dose-limiting Toxicities (DLTs) | Approximately 1 month | |
| Primary | Part 1a and Part 1b: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Treatment-related Adverse Events (TRAEs), and Serious Adverse Events (SAEs) | From first dose until 30 days after the last dose; approximately 13 months | |
| Secondary | Overall response rate (ORR) Assessed by Investigator | Approximately 24 months | ORR is defined as the percentage of participants with a best overall response of partial response or better per the Lugano Classification for non-Hodgkin lymphoma |
| Secondary | Complete response rate (CRR) | Approximately 24 months | CRR is defined as the percentage of participants with a best overall response of complete response per the Lugano Classification |
| Secondary | Duration of response (DOR) | Approximately 24 months | DOR is defined as the time from the first response to documented disease progression or death due to any cause, whichever occurs first |
| Secondary | Time to response (TTR) | Approximately 24 months | TTR is defined as the time from first dose to the first response |
| Secondary | Maximum Observed Plasma Concentration (Cmax) of BG-T0920 | Up to 1 month | |
| Secondary | Trough Concentration (Ctrough) of BG-T0920 | Up to 13 months | |
| Secondary | Area Under the Plasma Concentration-time Curve (AUC) of BG-T0920 | Up to 13 months | |
| Secondary | Serum concentration of BG-T0920 | Up to 13 months |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07887646
GET https://conductscience.org/api/trials/v1/NCT07887646/registered